drug
dexamethasone LA
Marketedupdated 3mo agoby $ABBV AbbVie Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 75 approved and 174 investigational indications.
indications
investigational
Diabetic Macular Edema
all catalysts(14)
approval · 14
Jun 17, 2009
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Aug 31, 2010
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 24, 2010
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 24, 2012
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 7, 2012
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 7, 2014
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Jun 28, 2014
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 26, 2014
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 5, 2016
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
May 15, 2018
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Oct 21, 2020
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Dec 19, 2022
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Mar 11, 2026
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
TBD
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Trials studying dexamethasone LA
- phase3Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- phase1A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
- phase3A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- phase3Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
- phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- phase2Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
- phase4An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
- phase2A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 7, 2028
~1.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Apr 26, 2041method-of-use (U-1680)US 12144889
- Jun 23, 2039formulationUS 11097061
- Nov 16, 2037method-of-use (U-3455)US 11458041
- Oct 7, 2036method-of-use (U-3455)US 12150896
- Jun 22, 2034method-of-use (U-2340)US 10022502
- May 23, 2034method-of-use (U-2340)US 10028965
- May 23, 2034formulationUS 10159683
- May 11, 2032formulationUS 10799642
- May 14, 2030formulationUS 84096063.7y
- Feb 12, 2030method-of-use (U-2487)US 85630273.5y
FDA exclusivities (1)
- Apr 7, 2028NPPNew Product (3y)1.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that